Compare TK & MRVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TK | MRVI |
|---|---|---|
| Founded | 1973 | 2014 |
| Country | Bermuda | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.0B |
| IPO Year | 1995 | 2020 |
| Metric | TK | MRVI |
|---|---|---|
| Price | $14.57 | $6.94 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $4.13 |
| AVG Volume (30 Days) | 518.0K | ★ 4.2M |
| Earning Date | 05-13-2026 | 05-07-2026 |
| Dividend Yield | ★ 15.21% | N/A |
| EPS Growth | N/A | ★ 14.29 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $185,743,000.00 |
| Revenue This Year | N/A | $12.54 |
| Revenue Next Year | N/A | $7.87 |
| P/E Ratio | $13.43 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $7.80 | $2.55 |
| 52 Week High | $14.93 | $9.42 |
| Indicator | TK | MRVI |
|---|---|---|
| Relative Strength Index (RSI) | 70.83 | 47.80 |
| Support Level | $12.11 | $6.49 |
| Resistance Level | N/A | $7.44 |
| Average True Range (ATR) | 0.45 | 0.31 |
| MACD | 0.06 | -0.09 |
| Stochastic Oscillator | 88.41 | 35.08 |
Teekay Corp Ltd provides international crude oil marine transportation and other marine services. It also offers offshore oil production, storage, and offloading services, under long-term, fixed-rate contracts. The company has two primary lines of business: Marine services and tankers. It manages these businesses for the benefit of all stakeholders. The company serves energy and utility companies, oil traders, large oil and LNG consumers, petroleum product producers, government agencies, and various other entities that depend upon marine transportation.
Maravai LifeSciences Holdings Inc is a life sciences company providing products and services to enable the development of drugs, therapeutics, vaccines and diagnostics, and to support research on human disease. Its product portfolio includes complex nucleic acids, custom enzymes and antibody-based solutions for therapeutic, vaccine, diagnostic and biopharmaceutical production applications. The Company operates through two segments: TriLink, which generates maximum revenue from North America and provides nucleic acid products and services including mRNA, oligonucleotides and related technologies; and Cygnus, which provides biologics safety testing products and services including host cell protein ELISA kits, impurity detection assays and related reagents and services.